Canaccord Genuity Group Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) Stock

Natera (NASDAQ:NTRA) had its price target hoisted by stock analysts at Canaccord Genuity Group from $200.00 to $250.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price objective indicates a potential upside of 25.27% from the company’s current price.

Several other research analysts also recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a report on Friday. BNP Paribas Exane raised Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Evercore ISI raised their price objective on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Morgan Stanley reissued an “overweight” rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Seventeen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus price target of $206.74.

Natera Stock Up 0.5%

Shares of NASDAQ NTRA opened at $199.57 on Friday. Natera has a 12 month low of $125.38 and a 12 month high of $203.23. The company has a market cap of $27.39 billion, a P/E ratio of -87.15 and a beta of 1.75. The business’s 50 day moving average is $177.75 and its two-hundred day moving average is $163.81.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, November 6th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.20% and a negative net margin of 14.61%.The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the previous year, the business posted ($0.26) EPS. The company’s revenue was up 34.7% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. Sell-side analysts expect that Natera will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $159.99, for a total transaction of $479,970.00. Following the completion of the transaction, the insider directly owned 117,559 shares in the company, valued at $18,808,264.41. This represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total value of $32,134,171.88. Following the transaction, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. The trade was a 52.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 224,889 shares of company stock valued at $43,232,062. 5.63% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the company. Bank of Jackson Hole Trust acquired a new position in Natera in the first quarter valued at about $29,000. Hilltop National Bank bought a new position in shares of Natera in the second quarter valued at approximately $33,000. Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera in the 2nd quarter worth approximately $36,000. Sound Income Strategies LLC boosted its holdings in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares in the last quarter. Finally, TCTC Holdings LLC grew its position in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.